Serum Hepcidin Immunoassay - Laboratory to Marketplace
Evaluation of the Intrinsic Hepcidin IDx™ Test to Detect Iron Deficiency and Predict Response to Oral Iron Therapy in Adolescents and Young Adults
Sponsor: Boston Children's Hospital
Listed as NCT03310736, this observational or N/A phase trial focuses on Anemia, Iron Deficiency and remains completed. Sponsored by Boston Children's Hospital, it has been updated 11 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Nov 2020 — Jan 2021 [monthly]
Completed
▶ Show 6 earlier versions
-
Sep 2020 — Nov 2020 [monthly]
Completed
-
Jul 2019 — Sep 2020 [monthly]
Completed
Status: Recruiting → Completed
-
Jun 2018 — Jul 2019 [monthly]
Recruiting
-
May 2018 — Jun 2018 [monthly]
Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Oct 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
Jun 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boston Children's Hospital
- Intrinsic LifeSciences, LLC
For direct contact, visit the study record on ClinicalTrials.gov .